Rare Disease Sales Projected to Exceed $400B by 2032 Despite Challenges, Driven by Small Molecule Resurgence

on

Orphan drug sales are projected to exceed $400 billion by 2032, up from $213 billion in the previous year, representing over 21% of global prescription pharma sales3568.

Small-molecule drugs account for 45% of the 20 most valuable orphan pipeline products by net present value, signaling a resurgence despite regulatory headwinds like the Inflation Reduction Act's pill penalty3.

Top orphan candidates include Revolution Medicines’ daraxonrasib, Priovant’s brepocitinib, and Cogent Biosciences’ bezuclastinib3.

Challenges include FDA inconsistencies (e.g., uniQure, Capricor, Biohaven cases) and competition from obesity drugs, but policy wins like the rare pediatric disease priority review voucher reinstatement support growth36.

A separate report forecasts the rare diseases treatment market to reach $45.82 billion by 2032 from $21.69 billion in 2025 (CAGR 11.17%), focusing on gene therapies and diagnostics4.

Sources:

3. https://www.biospace.com/business/rare-disease-sales-to-soar-to-400b-by-2032-as-small-molecules-resurgent-evaluate

4. https://www.businesswire.com/news/home/20251218382669/en/Rare-Diseases-Treatment-Market-Analysis-and-Forecast-2025-2032-A-$45.8-Billion-Opportunity---Complex-Challenges-and-Unprecedented-Opportunities-are-Emerging---ResearchAndMarkets.com

5. https://www.pharmaceuticalcommerce.com/view/rare-disease-drugs-poised-to-capture-over-21-of-global-pharma-sales-by-2032-report-finds

6. https://www.evaluate.com/thought-leadership/orphan-drugs-outlook-2032/

8. https://healtheconomics.com/rare-disease-drug-sales-projected-to-reach-409b-by-2032-despite-fda-volatility/